Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.
Nifedipine, the prototype for the dihydropyridine class of calcium antagonists, has been available for 20 years and its efficacy as a vasodilator and an antihypertensive agent is well recognised. The development of the so-called nifedipine gastrointestinal therapeutic system (GITS), which allows once-daily administration, has modified and improved the overall therapeutic profile of nifedipine to such a significant extent that it might almost be considered a new drug entity. The nifedipine GITS is associated with distinct improvements in terms of patient compliance and convenience, and a reduced incidence of adverse effects. With regard to the care of the elderly, this 'new' drug offers the prospect of a well tolerated and effective treatment without major cost implications.
Elliott
H L
HL
Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland.
Meredith
P A
PA
D000368:Aged; D000375:Aging / Q000097:blood*; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D003362:Cost-Benefit Analysis; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D006801:Humans; D009543:Nifedipine / Q000191:economics / Q000493:pharmacokinetics* / Q000494:pharmacology; D010349:Patient Compliance; D014665:Vasodilator Agents / Q000493:pharmacokinetics*
D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D009543:Nifedipine